Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian Equity markets remain in red
Fri, 26 Apr 11:30 am

Indian equity markets have witnessed selling pressures during the previous two hours of trade. realty and consumer durables are leading the pack of winners while banking and IT have faced the maximum selling pressures.

The BSE-Sensex is down by 93 points and NSE-Nifty is down by 37 points. BSE Mid Cap index is trading down by 0.01% while BSE Small Cap index is trading up by 0.07%. The rupee is trading at 54.24 to the US dollar.

Energy shares are trading on a mixed note with Castrol and Gas Authority Of India Ltd. (GAIL) leading the gains while Reliance Industries and Chennai Petroleum are facing the maximum selling pressures. According to a leading financial news medium, state-owned Hindustan Petroleum (HPCL) has received its board approval for incorporation of a joint venture (JV) company to set up a Rs 373 bn oil refinery and petrochemical complex in Rajasthan. It is planning to hold a 74% stake in the 9 million tonne a year refinery with Government of Rajasthan taking the balance 26%. The unit is planned to go on stream in four years. The refinery will run on crude oil from neighbouring oilfields of Cairn India. A part of the crude oil requirement at the proposed refinery will come from the Barmer oilfields of Cairn and the rest will be imported. Other than taking 26% stake, the state government has given in-principle approval for providing an interest free loan of Rs 37.3 bn per annum for 15 years from the date of commercial production. HPCL's share is trading up by 1.1%.

Pharma shares are trading on a mixed note with Elder Pharma and Natco Pharma leading the gains while Wockhardt Ltd and Biocon Ltd are facing the maximum selling pressures. Biocon has announced its 4QFY13 results. Revenue has grown by 7% YoY during the quarter and the below average growth in sales is largely due to poor growth in the Biopharmaceutical segment. However the domestic formulations and contract manufacturing segments has witnessed robust growth of above 30%. Operating margins has declined by 4.1% largely due to increase in staff costs. Margins have also been impacted due to higher licensing income in 4QFY13. On the other hand R&D expenses have been lower by 18%. Net profit has increased by 156% YoY during 4QFY13 due to an exceptional gain of Rs 2 bn during the quarter.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian Equity markets remain in red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.